Working in the healthcare publishing industry, it is important to be abreast of developing trends in the pharmaceutical market. The research firm Decision Resources recently reported that the market for obesity drugs will grow five-fold — to $2.7 billion — by 2016 (http://www.mmm-online.com/Obesity-market-set-for-explosive-growth-says-report/article/108301/). Growth is predicted to be most rapid in the US, but is also projected in the UK, France, Germany, Italy, Spain, and Japan.
The growth in the market is of course a direct result of new drugs being developed. In fact, the report predicts that 80% of the market will switch to using these new therapies, including Arena Pharmaceuticals’ lorcaserin and Amylin’s pramlintide/leptin combo.
“Given the high prevalence of obesity in the world’s major pharmaceutical markets, the opportunity for agents that fulfill the need for safe, effective and well-tolerated weight loss therapies is significant,” said Donny Wong, PhD., principal analyst at Decision Resources. Everyone is always going to be looking for a quick fix, be it for weight loss, clearing their skin, or changing a light bulb. But healthy, maintainable weight loss will never be achieved through these means. Instead I think we need to pay attention to the simple equation: eat less + exercise more = weigh less. We no doubt face obstacles — mainly the increasingly stressed out, sedentary US lifestyle and the abundance of cheap, high-calorie foods — but with education and dedication we may be able to see a more long-term effect.
Recent Comments